Start here if you're new
what it is
Lexeo develops gene therapies for heart disease and APOE4-linked Alzheimer's.
how it gets paid
Last year Lexeo Therapeutics made n/a in revenue. Cardiovascular gene therapy was the main engine at $0M, or 40% of sales.
what just happened
Lexeo lost $1.72 a share last quarter, which is the whole story when revenue is still $0M.
At a glance
B balance sheet — gets the job done, barely
-$3.09 fy2024 eps est
2.15 beta
~$486M market cap
small cap
xvary composite: 62/100 — average
What they do
Lexeo develops gene therapies for heart disease and APOE4-linked Alzheimer's.
Your edge is proof, not scale. Gene therapy means one-time DNA treatment. So what: one clean study can move this stock more than a normal quarter of sales would. Lexeo has 75 employees and two disease areas, so every data read matters.
How they make money
n/a
annual revenue
Cardiovascular gene therapy
$0M
APOE4 Alzheimer's program
$0M
J&J cardiac delivery collaboration
$0M
Platform research and biomarkers
$0M
The products that matter
balance sheet reality
cash and runway
$6M long-term debt
the debt load is only $6M, so the immediate balance-sheet issue is not leverage. it is how long current cash can fund trials before shareholders face dilution.
survival first
lead clinical programs
genetic medicine pipeline
~$486M equity story
at a market cap of about $486M, the lead pipeline is carrying most of the valuation. if the data read well, the stock gets a new narrative. if they do not, the old one disappears fast.
main catalyst
second shot on goal
platform optionality
$1–$11 range
the stock's $1–$11 52-week range tells you how unstable early-stage optionality is. until Lexeo proves it has more than one credible value driver, the market will keep treating the platform claim with caution.
proof needed
Key numbers
$7.20
share price
You are paying $7.20 for a pre-revenue biotech. That price lives and dies on trial updates.
$6M
long-term debt
That is tiny debt for a biotech. The balance sheet is not the main danger.
2.15
beta
This stock moves more than the market. Position size matters because the price can lurch on one headline.
75
employees
A 75-person company is still a lab with a ticker. That is the whole point here.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 1 — safer than 95% of stocks
- price stability 5 / 100
- long-term debt $6M (1% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for LXEO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Lexeo lost $1.72 a share last quarter, which is the whole story when revenue is still $0M.
This is a pre-revenue biotech, so the market is paying for clinical progress, not sales. The loss sits between a FY2024 EPS estimate of -$3.09 and a trailing EPS of -$1.32.
-$1.72
quarter eps
-$3.09
fy2024 eps
-$1.32
trailing eps
quarter loss
The $1.72 per-share loss matters because there is no sales cushion. That leaves trial data as the main driver.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is lead gene-therapy data failing to support the valuation. with no commercial revenue, there is no second engine to hide behind.
med
lead program data disappoints
This stock still trades like one clinical argument. If the lead genetic medicine programs miss on safety, efficacy, or both, the market does not have a fallback operating business to rerate.
At a ~$486M market cap and no revenue base, the repricing would hit the core thesis in one move.
med
dilution arrives before a validating readout
Pre-revenue biotech funds itself with cash on hand, partnerships, or new shares. If the trial calendar slips, shareholders are the funding source more often than not.
The damage is two-layered: more shares outstanding and a weaker signal about bargaining power.
med
gene therapy timelines stretch
Manufacturing, dosing, regulatory review, and patient enrollment all take longer than slide decks suggest. A delay does not kill the science, but it does change how long your capital is trapped.
For a stock with 5 / 100 price stability, time slippage alone can reset sentiment.
med
the platform story stays a slide, not a business
Biotech teams like to talk about platforms because investors like multiple shots on goal. Until Lexeo proves that with more than one credible value driver, the market will keep discounting the optionality.
If that happens, the stock keeps trading on a single-asset discount even if management uses broader language.
With no commercial revenue and an estimated FY2024 loss of -$3.09 per share, there is no operating cushion if data slip and financing moves up the calendar.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next corporate update
Use the next update to judge whether management is still talking in milestones and trial execution, not just broad platform language. Last full review: updated feb 20, 2026.
trend
does one program become more than one bet
The stock trades like a lead-asset biotech today. If Lexeo starts showing credible depth beyond the headline programs, the valuation framework changes with it.
risk
financing before validation
Keep watching the funding question before you watch the chart. For a pre-revenue biotech, a bad raise can matter almost as much as a bad dataset.
metric
price stability versus conviction
A 5 / 100 price stability score and a $1–$11 trading range tell you this name still moves on shifting probabilities. If the volatility stays high after better evidence, the market is telling you it still does not trust the story.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: there is no broad wall street agreement to lean on.
risk profile
volatile
a 2.15 beta and 5 / 100 price stability make the point. this name moves on catalysts, not calm accumulation.
chart momentum
stock-specific
the chart matters less than the next readout. biotech momentum can reverse on a single data release.
earnings predictability
40 / 100
that score is middling because the business is still changing shape. when you have no revenue, predictability is mostly about burn and timing.
source: institutional data
Institutional activity
institutional ownership data for LXEO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive